Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ViiV Healthcare

< Previous 1 2 Next >
News headline image
ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023
From ViiV Healthcare
Via Business Wire
News headline image
Major Corporations Launch New Coalition to Help End HIV in the United States
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare Unveils a New Global Study Revealing Three Quarters of People Believe There Are Still Negative Perceptions When It Comes to People Living With HIV
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare Presents Positive Data Showing Vocabria (cabotegravir) and Rekambys (rilpivirine) Can Be Successfully Implemented Across a Range of European Healthcare Settings
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare and the Medicines Patent Pool Sign New Voluntary Licensing Agreement to Expand Access to Innovative Long-Acting HIV Prevention Medicine
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
From ViiV Healthcare
Via Business Wire
News headline image
Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine), the first long-acting HIV-treatment regimen, can be implemented successfully in a variety of European healthcare settings
From ViiV Healthcare
Via Business Wire
News headline image
Less Talk, More Action: New Report Sponsored by ViiV Healthcare Provides Roadmap to Achieve Health Equity by 2040
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs
From ViiV Healthcare
Via Business Wire
News headline image
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
From ViiV Healthcare
Via Business Wire
Tickers PFE
News headline image
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
From ViiV Healthcare
Via Business Wire
News headline image
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From ViiV Healthcare
Via Business Wire
Tickers HALO PFE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.